
Recursion Pharmaceuticals, Inc.: updates and filings
Price
$2.83
November 18, 2026Market cap $1.8B
What Ploutos Investor adds for Recursion Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 29% since Nov 2, 2026, when the 10-Q these figures come from was filed ($3.83 then, $2.72 on Nov 17, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 2, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 2, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 2, 2026Results of operations, officer or director change, Regulation FD disclosureForm8-K
- Oct 15, 2026Material agreement entered, results of operations, Regulation FD disclosure, other material eventsForm8-K
- Sep 21, 2026Material agreement enteredForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 18, 2026Shareholder voteForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Apr 30, 2026Officer or director change, Regulation FD disclosureForm8-K
- Apr 24, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 25, 2026Officer or director change, Regulation FD disclosureForm8-K
- Feb 25, 2026Shares registered for employeesFormS-8
- Feb 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 2, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 2, 2026 | 8-K | Results of operations, officer or director change, Regulation FD disclosure | Document |
| Oct 15, 2026 | 8-K | Material agreement entered, results of operations, Regulation FD disclosure, other material events | Document |
| Sep 21, 2026 | 8-K | Material agreement entered | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 30, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Apr 24, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 25, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Feb 25, 2026 | S-8 | Shares registered for employees | Document |
| Feb 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 2, 2014.
The full analysis
What do Recursion Pharmaceuticals's filings show?
The filings are where every one of Recursion Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.